Delivery Order SPE2DB24D9113-SPE2DB25FEPXV

Award Date 3/21/25
Potential Completion Date 3/24/25
Potential Value $4.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,169.59 award is for the supply of 120 tablets of the prescription drug XTANDI 40 MG. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC enables the DLA to issue firm fixed-price delivery orders...
This is a delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the Medical Supply Chain program. The $4,169.59 firm fixed-price contract is for the delivery of XTANDI 80 MG TABLET 60S, a branded prescription medication. This delivery order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group valued at up to $499,999,999, which allows the DLA to issue orders...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,169.59, is for the delivery of 120 tablets of the prescription drug XTANDI 40 MG. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,311.35 order is for 120 capsules of the prescription drug XTANDI 40 MG. The order is part of a larger $499,999,999 indefinite-delivery contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a...
This is a $4,169.59 firm fixed-price delivery order contract awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA). The contract is for the delivery of XTANDI 80 MG TABLET 60S, a prescription drug product, with a performance period ending on June 5, 2024. The contract is issued under DMS Pharmaceutical Group's existing $499,999,999 indefinite delivery contract (IDC) with the DLA, which allows the agency to place delivery orders for a wide...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,311.35, is for the supply of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product. The delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which allows the DLA to issue...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,311.35, is for the delivery of 120 capsules of the drug XTANDI 40 MG. The contract does not have a set-aside designation and is valid through April 8, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,169.59, is for the delivery of 60 tablets of the prescription drug Xtandi 80 mg. The delivery order is part of a larger Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at $499,999,999 and valid through November 2026. This IDC allows the DLA to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,339.18 contract is for the delivery of XTANDI 40 MG TABLET 120S, a specialized pharmaceutical product. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,169.59 order is for the supply of XTANDI 80 MG TABLET 60S, a prescription drug, to support the medical needs of military healthcare facilities. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which...
  • SPE2DB24D9113
    Indefinite Delivery Contract
  • SPE2DB24D9113-SPE2DB25FEPXV
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $4,169.59, is for the supply of 120 tablets of the prescription drug XTANDI 40 MG. The delivery order was issued under an Indefinite Delivery Contract (IDC) worth $499,999,999 that DMS Pharmaceutical Group holds with the DLA, which allows the agency to order a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This contract is not associated with any set-aside designation, enabling DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across various medical product categories and support the recurring medical supply needs of military healthcare facilities and veterans' medical centers nationwide.

Generated 6/21/25, 9:54 AM